Gary Nachman
Stock Analyst at Raymond James
(3.80)
# 698
Out of 5,055 analysts
97
Total ratings
58.9%
Success rate
6.74%
Average return
Main Sectors:
Stocks Rated by Gary Nachman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| IONS Ionis Pharmaceuticals | Reiterates: Strong Buy | $85 → $89 | $71.55 | +24.39% | 4 | Oct 30, 2025 | |
| BLCO Bausch + Lomb | Reiterates: Outperform | $18 → $19 | $15.60 | +21.79% | 2 | Oct 30, 2025 | |
| LENZ LENZ Therapeutics | Reiterates: Outperform | $40 → $50 | $25.60 | +95.31% | 3 | Oct 20, 2025 | |
| ABBV AbbVie | Reiterates: Outperform | $236 → $250 | $232.36 | +7.59% | 17 | Oct 17, 2025 | |
| AMGN Amgen | Assumes: Market Perform | n/a | $336.74 | - | 2 | Sep 3, 2025 | |
| VERU Veru Inc. | Maintains: Outperform | $30 → $20 | $2.54 | +687.40% | 2 | Aug 13, 2025 | |
| SDGR Schrödinger | Maintains: Outperform | $25 → $28 | $17.64 | +58.73% | 5 | Nov 13, 2024 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $275 → $298 | $449.16 | -33.65% | 7 | Nov 1, 2024 | |
| ACHV Achieve Life Sciences | Initiates: Strong Buy | $20 | $4.38 | +356.62% | 1 | Sep 27, 2024 | |
| PCRX Pacira BioSciences | Maintains: Outperform | $41 → $37 | $23.78 | +55.59% | 13 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Strong Buy | $30 | $37.41 | -19.81% | 5 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $5.39 | +29.87% | 1 | Mar 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $141.07 | - | 11 | Sep 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $5 → $4 | $11.64 | -65.64% | 5 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $14.56 | +106.04% | 4 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $32 | $3.69 | +767.21% | 1 | Feb 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $16 → $14 | $10.72 | +30.60% | 2 | Feb 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $11 → $10 | $25.41 | -60.65% | 1 | Nov 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $30 | $41.94 | -28.47% | 2 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $810 → $750 | $3.59 | +20,791.36% | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $15 → $8 | $6.28 | +27.39% | 2 | Aug 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $20 → $21 | $26.06 | -19.42% | 5 | May 11, 2020 |
Ionis Pharmaceuticals
Oct 30, 2025
Reiterates: Strong Buy
Price Target: $85 → $89
Current: $71.55
Upside: +24.39%
Bausch + Lomb
Oct 30, 2025
Reiterates: Outperform
Price Target: $18 → $19
Current: $15.60
Upside: +21.79%
LENZ Therapeutics
Oct 20, 2025
Reiterates: Outperform
Price Target: $40 → $50
Current: $25.60
Upside: +95.31%
AbbVie
Oct 17, 2025
Reiterates: Outperform
Price Target: $236 → $250
Current: $232.36
Upside: +7.59%
Amgen
Sep 3, 2025
Assumes: Market Perform
Price Target: n/a
Current: $336.74
Upside: -
Veru Inc.
Aug 13, 2025
Maintains: Outperform
Price Target: $30 → $20
Current: $2.54
Upside: +687.40%
Schrödinger
Nov 13, 2024
Maintains: Outperform
Price Target: $25 → $28
Current: $17.64
Upside: +58.73%
Alnylam Pharmaceuticals
Nov 1, 2024
Maintains: Outperform
Price Target: $275 → $298
Current: $449.16
Upside: -33.65%
Achieve Life Sciences
Sep 27, 2024
Initiates: Strong Buy
Price Target: $20
Current: $4.38
Upside: +356.62%
Pacira BioSciences
Jul 31, 2024
Maintains: Outperform
Price Target: $41 → $37
Current: $23.78
Upside: +55.59%
Mar 28, 2024
Initiates: Strong Buy
Price Target: $30
Current: $37.41
Upside: -19.81%
Mar 28, 2024
Initiates: Outperform
Price Target: $7
Current: $5.39
Upside: +29.87%
Sep 29, 2023
Initiates: Market Perform
Price Target: n/a
Current: $141.07
Upside: -
Mar 3, 2023
Maintains: Market Perform
Price Target: $5 → $4
Current: $11.64
Upside: -65.64%
Mar 1, 2023
Maintains: Outperform
Price Target: $35 → $30
Current: $14.56
Upside: +106.04%
Feb 22, 2023
Maintains: Outperform
Price Target: $40 → $32
Current: $3.69
Upside: +767.21%
Feb 17, 2023
Downgrades: Market Perform
Price Target: $16 → $14
Current: $10.72
Upside: +30.60%
Nov 7, 2022
Maintains: Market Perform
Price Target: $11 → $10
Current: $25.41
Upside: -60.65%
Nov 4, 2022
Maintains: Outperform
Price Target: $40 → $30
Current: $41.94
Upside: -28.47%
Aug 11, 2022
Maintains: Outperform
Price Target: $810 → $750
Current: $3.59
Upside: +20,791.36%
Aug 10, 2022
Maintains: Market Perform
Price Target: $15 → $8
Current: $6.28
Upside: +27.39%
May 11, 2020
Maintains: Market Perform
Price Target: $20 → $21
Current: $26.06
Upside: -19.42%